| Gut microbiota and health | Lifetime | 43 | CN 1 | 99.79 |
| Liver Disease Diagnosis and Treatment | Lifetime | 219 | CN 9 | 99.65 |
| COVID-19 Clinical Research Studies | Lifetime | 144 | CN 28 | 99.20 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 158 | CN 27 | 99.28 |
| Liver physiology and pathology | Lifetime | 60 | CN 5 | 99.25 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 99 | CN 2 | 99.05 |
| Hepatitis B Virus Studies | Lifetime | 281 | CN 12 | 99.18 |
| Ferroptosis and cancer prognosis | Lifetime | 134 | CN 54 | 98.05 |
| Mesenchymal stem cell research | Lifetime | 229 | CN 25 | 98.69 |
| Liver Disease and Transplantation | Lifetime | 349 | CN 8 | 99.03 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 350 | CN 7 | 98.86 |
| Diet and metabolism studies | Lifetime | 796 | CN 13 | 98.64 |
| Antibiotic Resistance in Bacteria | Lifetime | 527 | CN 29 | 98.42 |
| MicroRNA in disease regulation | Lifetime | 858 | CN 317 | 97.58 |
| Probiotics and Fermented Foods | Lifetime | 476 | CN 24 | 98.05 |
| Hepatitis C virus research | Lifetime | 675 | CN 26 | 98.24 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 346 | CN 16 | 97.32 |
| Clinical Nutrition and Gastroenterology | Lifetime | 364 | CN 3 | 97.35 |
| Long-Term Effects of COVID-19 | Lifetime | 688 | CN 48 | 95.46 |
| Tissue Engineering and Regenerative Medicine | Lifetime | 654 | CN 69 | 96.69 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 924 | CN 73 | 96.27 |
| Influenza Virus Research Studies | Lifetime | 789 | CN 68 | 96.82 |
| COVID-19 diagnosis using AI | Lifetime | 564 | CN 105 | 91.75 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 831 | CN 51 | 93.29 |
| Infections and bacterial resistance | Lifetime | 965 | CN 67 | 74.35 |
| Gut microbiota and health | 2021-2025 | 11 | CN 6 | 99.83 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 77 | CN 6 | 99.54 |
| Diet and metabolism studies | 2021-2025 | 81 | CN 8 | 98.86 |
| Ferroptosis and cancer prognosis | 2021-2025 | 63 | CN 46 | 98.71 |
| Liver physiology and pathology | 2021-2025 | 12 | CN 3 | 98.01 |
| Mesenchymal stem cell research | 2021-2025 | 38 | CN 19 | 97.38 |
| MicroRNA in disease regulation | 2021-2025 | 117 | CN 78 | 98.19 |
| Cancer-related molecular mechanisms research | 2021-2025 | 203 | CN 155 | 98.20 |
| RNA modifications and cancer | 2021-2025 | 233 | CN 156 | 97.72 |
| Immune cells in cancer | 2021-2025 | 193 | CN 111 | 96.02 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 60 | CN 8 | 95.52 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 121 | CN 26 | 94.62 |
| Liver Disease and Transplantation | 2021-2025 | 392 | CN 17 | 96.08 |
| Gastrointestinal motility and disorders | 2021-2025 | 141 | CN 11 | 94.49 |
| Hepatitis B Virus Studies | 2021-2025 | 350 | CN 63 | 94.01 |
| Hepatitis C virus research | 2021-2025 | 370 | CN 40 | 94.10 |
| Probiotics and Fermented Foods | 2021-2025 | 453 | CN 198 | 93.25 |
| Liver Diseases and Immunity | 2021-2025 | 214 | CN 12 | 92.65 |
| Organ Transplantation Techniques and Outcomes | 2021-2025 | 560 | CN 16 | 92.54 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 541 | CN 204 | 88.56 |
| Tryptophan and brain disorders | 2021-2025 | 630 | CN 190 | 90.08 |
| Circular RNAs in diseases | 2021-2025 | 570 | CN 410 | 89.82 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 686 | CN 204 | 88.82 |
| Diet, Metabolism, and Disease | 2021-2025 | 493 | CN 80 | 88.37 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 745 | CN 143 | 88.85 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 574 | CN 126 | 80.29 |
| Cancer Mechanisms and Therapy | 2021-2025 | 672 | CN 286 | 76.40 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 513 | CN 89 | 74.89 |
| Digestive system and related health | 2021-2025 | 555 | CN 123 | 68.10 |
